Review summary
Teaching objective: Polypharmacy and prescription opioid and sedative use disorders from several prescribers, in a 39-year-old touring singer who comes in for fatigue, weight gain, constipation, sleepiness and high blood pressure. The episode covers a brown-bag medication reconciliation and prescription drug monitoring program review that finds two opioids, two benzodiazepines and an appetite suppressant from five prescribers; a nonjudgmental DSM-5-TR assessment; naloxone at the first visit; a single-prescriber agreement; buprenorphine started in the office under the ASAM 2020 guideline, with the guideline's advice that taking a benzodiazepine is not a reason to withhold it; the benzodiazepines combined into diazepam and tapered slowly under the 2025 joint guideline; a structured safety assessment with means safety and the 988 Suicide & Crisis Lifeline; hypertension confirmed with home readings and treated under the 2025 AHA/ACC guideline; obesity treated without stigma with tirzepatide, which also treats obstructive sleep apnea; STOP-Bang and in-laboratory polysomnography because opioids make home testing unreliable; opioid-induced constipation; glaucoma that rules out phentermine and anticholinergic sleep aids; acute back pain managed on buprenorphine; and care planned around a performing and touring schedule.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| January 8, 1935 | Born in Tupelo, Mississippi. | CLM-0001 |
| 1953 | First recording; national fame from 1956; Army service from 1958 to 1960; Las Vegas engagements and tours in the 1970s. Believed never to have smoked or drunk alcohol. | CLM-0002, CLM-0011 |
| 1971 | Acute angle-closure glaucoma; under an ophthalmologist's care from then on. | CLM-0007 |
| October 15, 1973 | Hospital stay in Memphis under an assumed name; later testimony says he was withdrawn from narcotic drugs. | CLM-0003 |
| July 1974 | A few weeks off at Graceland after a year of engagements and tours. | CLM-0002 |
| August 19, 1974 | Las Vegas engagement, then a tour from September 27 to October 14. | CLM-0015 |
| January 28, 1975 | Two hospital stays in 1975, for abdominal problems and swelling and then for breathlessness and swelling; reported treatment for hypertension and a blocked, enlarged colon. | CLM-0004, CLM-0005 |
| 1975 to 1977 | About 19,000 doses of stimulants, sedatives and painkillers prescribed by one physician in his last 30 months, with drugs also from other sources. | CLM-0009 |
| August 16, 1977 | Dies at Graceland at 42; the cause is disputed. Overweight in his last years; his glaucoma is later interpreted as steroid-induced. | CLM-0012, CLM-0013, CLM-0014, CLM-0006, CLM-0008 |
| November 4, 1981 | His physician is acquitted of overprescribing after testimony that he was addicted to prescribed drugs. | CLM-0010 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Elvis Aron Presley was born in a two-room house in Tupelo, Mississippi, on January 8, 1935; his family moved to Memphis when he was 13. | confirmed | Ivins M. Elvis Presley Dies; Rock Singer Was 42. The New York Times, August 17, 1977 (On This Day archive) supports HISTMED Master Roster v3 context |
| D | He made his first record in 1953, became a national star in 1956, served in the Army in West Germany from 1958 to 1960, and by the 1970s performed long engagements in Las Vegas and toured constantly. In 1974 he played Las Vegas from January 26 to February 9, toured through much of March, including four shows in Memphis on March 16 and 17 and a recorded show there on March 20, played Lake Tahoe from May 16 to 26, toured again in mid-June, and took a few weeks off at Graceland from early July. Anchors the performing and touring schedule in the modern social history and the timing of the index visit. |
confirmed | Ivins M. Elvis Presley Dies; Rock Singer Was 42. The New York Times, August 17, 1977 (On This Day archive) supports Elvis History: 1974-1977 supports |
| D | From October 15 to November 1, 1973, he was treated at Baptist Memorial Hospital in Memphis under an assumed name; at the 1981 trial of his physician, an internal medicine specialist who reviewed the records testified that the consulting physicians were "withdrawing him from narcotic drugs." The anchor for the synthetic opioid use disorder; recorded as trial testimony reported by a wire service. |
confirmed | Elvis Presley was a drug addict and was hospitalized (UPI, October 23, 1981) supports |
| D | He was treated at Baptist Hospital again from January 28 to February 13, 1975, when the admission note recorded abdominal problems and swelling of the face, hands and legs, and from August 21 to September 25, 1975, for shortness of breath and swelling. In 1977 the medical examiner said that the drugs he found were those prescribed for hypertension and a blockage of the colon, for which Presley had been hospitalized twice in 1975. History after the index visit; anchors the synthetic hypertension and constipation. |
confirmed | Elvis Presley was a drug addict and was hospitalized (UPI, October 23, 1981) supports Ivins M. Elvis Presley Dies; Rock Singer Was 42. The New York Times, August 17, 1977 (On This Day archive) supports HISTMED Master Roster v3 context |
| D | In 1977 an unnamed Baptist Hospital employee told Rolling Stone that he had been treated there for "hypertension, enlarged colon, gastroenteritis, stomach inflammation," had "a severe liver condition," had received cortisone, and weighed at least 230 pounds; the hospital's doctors discounted a suggestion of lupus. An anonymous contemporary report; recorded as history only and not used for any modern diagnosis beyond the synthetic liver tests. |
probable | Flippo C. Elvis Presley: Funeral in Memphis. Rolling Stone, 1977 supports |
| D | He was about six feet tall and had once weighed about 175 pounds; in his last years he was reported to be overweight and at times appeared bloated on stage. Anchors the synthetic weight gain and obesity, which the modern episode treats without stigma. |
confirmed | Ivins M. Elvis Presley Dies; Rock Singer Was 42. The New York Times, August 17, 1977 (On This Day archive) supports HISTMED Master Roster v3 context |
| D | He had glaucoma, including an episode of acute angle-closure glaucoma in 1971, and was under the care of one ophthalmologist from 1971 on. Anchors the synthetic glaucoma and the ophthalmology follow-up. |
confirmed | Zegers RH, Liu KC, Heutink J, Tennant F, Weinreb RN. Suspicious eyes - Elvis's glaucoma battle. J Med Biogr 2025;33(2):112-115 (PMID 39150457) supports HISTMED Master Roster v3 context |
| R | A 2025 ophthalmology review interprets his glaucoma as steroid-induced, from lifelong use of steroids both prescribed and self-administered, with secondary angle closure most likely due to anterior uveitis. Retrospective interpretation; the modern diagnosis of glaucoma secondary to drugs is synthetic. |
probable | Zegers RH, Liu KC, Heutink J, Tennant F, Weinreb RN. Suspicious eyes - Elvis's glaucoma battle. J Med Biogr 2025;33(2):112-115 (PMID 39150457) supports |
| D | At the 1981 trial of his physician, George Nichopoulos, prosecutors showed that the physician had prescribed about 19,000 doses of stimulants, sedatives and painkillers for him in the last 30 months of his life, including 1,679 addictive pills in 205 days between the two 1975 hospital stays; the defense argued that he obtained drugs from many other sources, including amphetamines mailed from the West Coast, and a detective testified to collecting prescriptions from 140 Memphis pharmacies. Documented history of prescribed controlled drugs from several sources; anchors the synthetic multiple-prescriber history, the prescription drug monitoring program review and the single-prescriber agreement. No decision or statement in the modern episode is attributed to any real person. |
confirmed | Murphy P. Details of Presley's death still unknown (UPI, November 7, 1981) supports Elvis Presley was a drug addict and was hospitalized (UPI, October 23, 1981) supports Elvis Presley was a drug addict and received 'staggering' amounts of drugs (UPI, October 13, 1981) supports HISTMED Master Roster v3 context |
| D | Testimony at the trial described him as addicted to prescribed stimulants, sedatives and painkillers; the internal medicine specialist testified, "Absolutely. He was addicted." On November 4, 1981, the jury acquitted the physician of overprescribing, citing his efforts to substitute placebos and intercept drugs sent from elsewhere; the physician then said that drugs "may have played a part" in the death. History after the modern episode; recorded without blame and without a modern statement attributed to any real person. |
confirmed | Elvis Presley was a drug addict and was hospitalized (UPI, October 23, 1981) supports Murphy P. Details of Presley's death still unknown (UPI, November 7, 1981) supports Thorsberg F. Jurors say Elvis doctor operated in good faith (UPI, November 5, 1981) supports |
| D | It was believed that he neither smoked nor drank alcohol. Anchors the synthetic alcohol and tobacco history. |
probable | Ivins M. Elvis Presley Dies; Rock Singer Was 42. The New York Times, August 17, 1977 (On This Day archive) supports |
| D | On August 16, 1977, at 42, he was found unresponsive on the floor of his bathroom at Graceland, his home in Memphis, and was pronounced dead at Baptist Memorial Hospital. History only, recorded in one plain sentence. |
confirmed | Ivins M. Elvis Presley Dies; Rock Singer Was 42. The New York Times, August 17, 1977 (On This Day archive) supports Wakeman G. How Did Elvis Presley Die? supports Elvis History: 1974-1977 supports HISTMED Master Roster v3 context |
| R | The cause of his death is disputed. The medical examiner gave cardiac arrhythmia, citing a history of mild hypertension and evidence of coronary artery disease, and later ruled it heart disease; the autopsy report was never released. Trial testimony said that 14 drugs, including codeine at ten times the maximum accepted level, were found in tissue samples, and later accounts attribute the death to multiple prescription drugs, to heart disease, or to straining with a severely enlarged colon. History only; no cause of death is assumed in the modern episode. |
disputed | Ivins M. Elvis Presley Dies; Rock Singer Was 42. The New York Times, August 17, 1977 (On This Day archive) supports Elvis Presley was a drug addict and was hospitalized (UPI, October 23, 1981) supports Murphy P. Details of Presley's death still unknown (UPI, November 7, 1981) supports Wakeman G. How Did Elvis Presley Die? supports HISTMED Master Roster v3 context |
| R | His physician later said that he had a severe form of megacolon, his colon about twice its normal diameter and impacted with stool at his death. Reported second-hand in a 2026 article quoting a biographer; recorded as a possibility only. |
possible | Wakeman G. How Did Elvis Presley Die? supports HISTMED Master Roster v3 context |
| D | After the weeks off in July 1974 he played the Las Vegas Hilton from August 19 to September 2, talking on stage about karate, and toured from September 27 to October 14, ending at Lake Tahoe on October 11 to 14. History after the index visit; the modern episode plans care around the same engagements. |
confirmed | Elvis History: 1974-1977 supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings | resolved | confirmed | active | CLM-0003, CLM-0009, CLM-0010, CLM-0006 |
| S | Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working | active | confirmed | both_with_link | CLM-0006 |
| S | Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided | active | confirmed | both_with_link | CLM-0007, CLM-0008 |
| S | Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillers | active | confirmed | both_with_link | CLM-0003, CLM-0009, CLM-0010 |
| S | Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedatives | active | confirmed | both_with_link | CLM-0003, CLM-0009, CLM-0010 |
| S | Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normal | active | confirmed | both_with_link | CLM-0004 |
| S | Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAP | active | confirmed | active | |
| S | Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm features | active | confirmed | both_with_link | CLM-0004, CLM-0014 |
| S | Acute low back strain after karate practice, without radicular signs or red flags, in a man on buprenorphine; resolved | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-07-10 | Hemoglobin [Mass/volume] in Blood | 15.1 g/dL Reference 13.2-17.1 g/dL |
http://loinc.org · 718-7 |
| S | 2026-07-10 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-07-10 | Potassium [Moles/volume] in Serum or Plasma | 4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-07-10 | Creatinine [Mass/volume] in Serum or Plasma | 1 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-07-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 98 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-07-10 | Glucose [Mass/volume] in Serum or Plasma | 104 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-07-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.8% (high) Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-07-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 72 U/L (high) Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-07-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 U/L (high) Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-07-10 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 78 U/L (high) Reference 8-61 U/L |
http://loinc.org · 2324-2 |
| S | 2026-07-10 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 mIU/L Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-07-10 | Albumin/Creatinine [Mass Ratio] in Urine | 14 mg/g{creat} Reference <=29 mg/g{creat} |
http://loinc.org · 9318-7 |
| S | 2026-07-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | http://loinc.org · 44261-6 |
| S | 2026-07-10 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | http://loinc.org · 70274-6 |
| S | 2026-07-10 | Total score [DAST-10] | 7 | http://loinc.org · 82667-7 |
| S | 2026-07-10 | Total score [AUDIT-C] | 0 | http://loinc.org · 75626-2 |
| S | 2026-08-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 2026-08-14 | Cholesterol [Mass/volume] in Serum or Plasma | 214 mg/dL (high) Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-08-14 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 mg/dL (low) Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-08-14 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 140 mg/dL (high) Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-08-14 | Triglyceride [Mass/volume] in Serum or Plasma | 180 mg/dL (high) Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-08-07 | Potassium [Moles/volume] in Serum or Plasma | 4.4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-08-07 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-08-07 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 94 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-08-07 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-08-07 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | http://loinc.org · 70274-6 |
| S | 2026-09-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 2026-09-23 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | http://loinc.org · 70274-6 |
| S | 2026-10-28 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-10-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 96 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-10-28 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-10-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-10-28 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-10-28 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 55 U/L Reference 8-61 U/L |
http://loinc.org · 2324-2 |
| S | 2026-10-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-10-28 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | http://loinc.org · 70274-6 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-07-10 | Body height | 183 cm | 8302-2 | S |
| 2026-07-10 | Body weight | 109 kg | 29463-7 | S |
| 2026-07-10 | Body mass index (BMI) [Ratio] | 32.5 kg/m2 | 39156-5 | S |
| 2026-07-10 | Systolic blood pressure | 154 mm[Hg] | 8480-6 | S |
| 2026-07-10 | Diastolic blood pressure | 98 mm[Hg] | 8462-4 | S |
| 2026-07-10 | Heart rate | 94 /min | 8867-4 | S |
| 2026-07-10 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-07-10 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-07-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 2026-07-17 | Body height | 183 cm | 8302-2 | S |
| 2026-07-17 | Body weight | 108.6 kg | 29463-7 | S |
| 2026-07-17 | Body mass index (BMI) [Ratio] | 32.4 kg/m2 | 39156-5 | S |
| 2026-07-17 | Systolic blood pressure | 146 mm[Hg] | 8480-6 | S |
| 2026-07-17 | Diastolic blood pressure | 94 mm[Hg] | 8462-4 | S |
| 2026-07-17 | Heart rate | 102 /min | 8867-4 | S |
| 2026-07-17 | Respiratory rate | 18 /min | 9279-1 | S |
| 2026-07-17 | Body temperature | 37 Cel | 8310-5 | S |
| 2026-07-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 2026-08-07 | Body height | 183 cm | 8302-2 | S |
| 2026-08-07 | Body weight | 108.2 kg | 29463-7 | S |
| 2026-08-07 | Body mass index (BMI) [Ratio] | 32.3 kg/m2 | 39156-5 | S |
| 2026-08-07 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-08-07 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-08-07 | Heart rate | 76 /min | 8867-4 | S |
| 2026-08-07 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-07 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-08-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-09-23 | Body height | 183 cm | 8302-2 | S |
| 2026-09-23 | Body weight | 105.1 kg | 29463-7 | S |
| 2026-09-23 | Body mass index (BMI) [Ratio] | 31.4 kg/m2 | 39156-5 | S |
| 2026-09-23 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-09-23 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-09-23 | Heart rate | 74 /min | 8867-4 | S |
| 2026-09-23 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-23 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-10-28 | Body height | 183 cm | 8302-2 | S |
| 2026-10-28 | Body weight | 102.6 kg | 29463-7 | S |
| 2026-10-28 | Body mass index (BMI) [Ratio] | 30.6 kg/m2 | 39156-5 | S |
| 2026-10-28 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-10-28 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-10-28 | Heart rate | 70 /min | 8867-4 | S |
| 2026-10-28 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-28 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-08-14 | Body height | 183 cm | 8302-2 | S |
| 2026-08-14 | Body weight | 107.6 kg | 29463-7 | S |
| 2026-08-14 | Body mass index (BMI) [Ratio] | 32.1 kg/m2 | 39156-5 | S |
| 2026-08-14 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-08-14 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-08-14 | Heart rate | 74 /min | 8867-4 | S |
| 2026-08-14 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-14 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-09-09 | Body height | 183 cm | 8302-2 | S |
| 2026-09-09 | Body weight | 106 kg | 29463-7 | S |
| 2026-09-09 | Body mass index (BMI) [Ratio] | 31.7 kg/m2 | 39156-5 | S |
| 2026-09-09 | Systolic blood pressure | 134 mm[Hg] | 8480-6 | S |
| 2026-09-09 | Diastolic blood pressure | 84 mm[Hg] | 8462-4 | S |
| 2026-09-09 | Heart rate | 84 /min | 8867-4 | S |
| 2026-09-09 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-09 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-09-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Singer and performer since his teens; long engagements in Las Vegas and multi-week concert tours with two shows on some nights; between tours he is at his home in Memphis. A three-week Las Vegas engagement begins in about six weeks and a tour after that
- S Lives at his home in Memphis with household staff and friends who work for him and travel with him on tour
- S Prescriptions from five prescribers filled at three pharmacies over the past year, by the prescription drug monitoring program; says he started opioids for back and neck pain from performing, and sedatives for sleep after shows; also a nonprescription diphenhydramine sleep aid most nights, stopped today because of his glaucoma and the sedatives; no pills from any source other than a prescription or a pharmacy shelf; never injected
- S Alcohol: none (AUDIT-C 0). Tobacco: never
- S Eats one large meal after shows late at night; snacks on the tour bus; little activity between tours apart from karate practice
- S Keeps several firearms at home; agreed today to store them locked and unloaded, with ammunition separate, while the medicines are being changed
- S Strengths: devotion to his audience and his music, his faith and gospel singing, loyalty to the people around him, and his own decision to change how he takes his medicines
Functional status
- S Independent in all activities; sleeps late after shows and is drowsy through the afternoon; has fallen asleep in the car as a passenger; does not drive himself at present. Epworth Sleepiness Scale 14 (excessive daytime sleepiness); STOP-Bang 6 of 8 (snoring, tiredness, observed pauses, high blood pressure, BMI above 35 not met, neck 44 cm, male); neck circumference 44 cm
Mental status
- S Polite, warm and soft-spoken; a little slowed with small pupils, without slurred speech; no signs of withdrawal; candid once reassured that the visit is not about blame
- S Mood tired and worried; PHQ-9 8 with item 9 scored 0, GAD-7 9; no thoughts of suicide or self-harm now or in the past
Structured safety assessment
This assessment is synthetic and does not convert historical behavior into a present-day fact.
Allergies and medications
Allergies
- S No known allergy
Medications
- S Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation
- S Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation
- S Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time
- S Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time
- S Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma
- S Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist
- S Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag
- S Polyethylene glycol 3350, 17 g powder in a glass of water once daily
- S Senna 8.6 mg oral tablet, two tablets at bedtime
- S Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only
- S Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable
- S Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time
- S Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg)
- S Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily
- S Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly
- S Tirzepatide 5 mg/0.5 mL auto-injector, 5 mg under the skin once weekly
- S Naproxen 500 mg oral tablet, one tablet twice daily with food for five days
Procedures and immunizations
Procedures
- S Twelve-lead electrocardiogram at the evaluation of high blood pressure readings, before any change in his medicines: sinus rhythm at 92, normal axis, no left ventricular hypertrophy, QTc 436 ms
- S Attended in-laboratory split-night polysomnography (chosen over home testing because he takes opioids and benzodiazepines): apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80%; CPAP titrated to 11 cm H2O, which controlled events
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 2026-08-14: Tdap vaccine; last tetanus booster more than ten years ago
- S 2026-09-23: Hepatitis B vaccine (HepB-CpG), first of two doses, after serology showed no immunity
- S 2026-10-28: Hepatitis B vaccine (HepB-CpG), second of two doses
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1971: Glaucoma, with an acute angle-closure episode treated years earlier; under an ophthalmologist's care since (CLM-0007)
- D October 15, 1973: Hospital stay of about two weeks in which, by later testimony, he was withdrawn from narcotic drugs; recorded without detail (CLM-0003)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Stop full-agonist opioids and stabilize on buprenorphine without significant withdrawal | 2026-08-07 | completed | Buprenorphine 16 mg a day since the consultation; no withdrawal after the first day; cravings low |
| One prescriber and one pharmacy for all controlled medicines | 2026-09-23 | completed | Monitoring program shows only this clinic's prescriptions since intake |
| Lower the diazepam dose slowly, 5 to 10% every two to four weeks, toward stopping | 2026-10-28 | active | 40 mg a day after the alprazolam was combined into it, to 30 mg at four months; no withdrawal symptoms; taper continuing |
| Home blood pressure below 130/80 | 2026-08-07 | completed | Home average 146/94 to 126/80 on amlodipine and valsartan |
| Lose 5% or more of body weight | 2026-10-28 | completed | 109.0 to 102.6 kg (5.9%) on tirzepatide, with more activity and earlier meals |
| CPAP on at least 70% of nights for four hours or more, with less daytime sleepiness | 2026-10-28 | completed | CPAP on 88% of nights; Epworth 14 to 6 |
| A bowel movement at least every two days without straining | 2026-08-07 | completed | Every one to two days on buprenorphine and polyethylene glycol |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Safe prescribing of controlled drugs: a brown-bag reconciliation of every medicine, a prescription drug monitoring program check before every controlled prescription, a written single-prescriber agreement with one pharmacy, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused tablets; no controlled drug stopped abruptly | completed | GL-CDC-OPIOID-2022, GL-CDC-PDMP, GL-BZD-TAPER-2025 |
| Addiction medicine consultation to make the substance use diagnoses, start medication for opioid use disorder, and plan the benzodiazepine change and taper | completed | GL-ASAM-OUD-2020, GL-BZD-TAPER-2025 |
| Overdose prevention: naloxone nasal spray at home and in the tour bag, two people around him taught to use it, no alcohol or other sedatives, and the danger of opioids with benzodiazepines and with the sleep apnea that is suspected explained | completed | GL-CDC-OPIOID-2022, GL-ASAM-OUD-2020 |
| Safety: a structured safety assessment, a written safety plan, firearms locked and unloaded with ammunition separate, the 988 Suicide & Crisis Lifeline, and safety review at every visit; PHQ-9 and GAD-7 at each review | completed | GL-SUICIDE-2024, GL-USPSTF-DEP-2023, GL-CMID-2026 |
| Buprenorphine for opioid use disorder: buprenorphine with naloxone started in the office at a COWS score above 8, 16 mg a day, weekly contact for the first month, prescriptions from this clinic only, counseling, and no tapering off while he is doing well; buprenorphine is not withheld because he takes a benzodiazepine | completed | GL-ASAM-OUD-2020, GL-CDC-OPIOID-2022 |
| Benzodiazepine change and taper: alprazolam combined into diazepam (40 mg a day), held steady until buprenorphine is stable, then reduced by about 5 to 10% every two to four weeks, paused during engagements, illness or withdrawal symptoms, never stopped abruptly; CBT for anxiety and insomnia alongside; no Z-drug or other sedative in its place | completed | GL-BZD-TAPER-2025 |
| Hypertension: home readings confirmed stage 2 hypertension, so two first-line drugs were started in one pill (amlodipine with valsartan), with potassium and creatinine two to four weeks later, a target below 130/80, sodium reduction, activity and weight loss | completed | GL-AHA-HTN-2025, GL-CMID-2026 |
| Obstructive sleep apnea: CPAP from the split-night titration, with adherence data reviewed at each visit and a travel machine for tours; no sedative added at night | completed | GL-AASM-PAP-2019, GL-AASM-DX-2017 |
| Weight treated without stigma: earlier meals, protein and fiber, more walking and karate between tours, and tirzepatide once weekly, chosen because it also treats obstructive sleep apnea with obesity, raised slowly with a watch on nausea and constipation | completed | GL-AGA-OBESITY-2022, GL-SURMOUNT-OSA-2024 |
| Constipation on opioids: polyethylene glycol daily with senna as needed, fluids and fiber; a peripherally acting opioid antagonist only if these fail; an abdominal radiograph only for pain, distension or vomiting | completed | GL-AGA-OIC-2019, GL-AGA-ACG-CIC-2023 |
| Glaucoma: latanoprost continued, his ophthalmologist kept informed of every new medicine, no phentermine, decongestant or anticholinergic sleep aid, steroids only when essential and with his ophthalmologist's knowledge, and urgent care for eye pain with halos | completed | GL-AAO-POAG-2020, GL-CMID-2026 |
| Performing and touring: no medication change in the week before an engagement, weekly video visits while away, controlled prescriptions sent only to one named pharmacy, a written plan for missed doses, naloxone and any prescribed devices in the tour bag, and a letter he controls for venues | completed | GL-ASAM-OUD-2020, GL-BZD-TAPER-2025 |
Planned encounters
- 2026-07-10 — Establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral (ENC-001)
- 2026-07-17 — One-week review, seen the same day by addiction medicine: diagnoses, buprenorphine started in the office, the benzodiazepines combined into one, the sleep study and home blood pressure results (ENC-002)
- 2026-08-07 — Three-week review on buprenorphine: withdrawal and cravings, the first benzodiazepine taper step, blood pressure treatment, CPAP, constipation and weight, and planning for a Las Vegas engagement (ENC-003)
- 2026-08-14 — Periodic adult preventive visit (ENC-006)
- 2026-09-09 — Same-day sick visit for low back pain (ENC-007, unscheduled)
- 2026-09-23 — Ten-week review after the Las Vegas engagement and a back strain: buprenorphine, the taper, weight treatment, sleep apnea and planning for a three-week tour (ENC-004)
- 2026-10-28 — Four-month review after the tour: recovery, the taper, blood pressure, weight, liver tests, sleep and the plan ahead (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Preventive Visit
- Progress note 05 — Sick Visit
- Progress note 06 — Focused Visit (Follow-up)
- Progress note 07 — Focused Visit (Care-plan review)
- Addiction Medicine referral
- Addiction Medicine consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Preventive Visit (XML)
- Progress note 05 — Sick Visit (XML)
- Progress note 06 — Focused Visit (Follow-up) (XML)
- Progress note 07 — Focused Visit (Care-plan review) (XML)
- Addiction Medicine referral (XML)
- Addiction Medicine consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the DSM-5-TR criteria counts (tolerance and withdrawal counted because use was not as prescribed), the MME totals, the one-week delay before buprenorphine at his choice with naloxone and seven-day supplies in between, the in-office induction, buprenorphine with a benzodiazepine, the alprazolam to diazepam conversion and the taper pace, amlodipine with valsartan as a single pill for stage 2 hypertension, tirzepatide for obesity with obstructive sleep apnea while on buprenorphine, in-laboratory polysomnography on opioids, stopping phentermine for glaucoma and blood pressure, and acute back pain treated by splitting the buprenorphine dose with naproxen. |
| provenance review | not_started | Sources: The New York Times obituary (1977), Graceland's official timeline, four UPI wire reports of the 1981 trial, the 1977 Rolling Stone report, a HISTORY article (2026), and the PubMed abstract of Zegers et al. (2025). The Commercial Appeal could not be reached and the biographies were not read. The cause of death is graded R and disputed; the steroid explanation of his glaucoma is R, probable; the megacolon account is R, possible. |
| safe messaging review | not_started | Drug and mental-health claims are marked sensitive; the 1973 hospital stay and the trial testimony are recorded without detail beyond the reports; his death is recorded in one plain sentence and its disputed cause separately; person-first language; weight is described without stigma; the safety assessment gives the 988 Suicide & Crisis Lifeline and addresses means safety, including firearms. His physician appears only in documented history, with no modern decision or statement attributed to him; no living person is named, and nothing is attributed to his former wife or his daughter. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.